NCT01952015 - Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 21, 2013

Primary Completion Date

March 15, 2016

Study Completion Date

March 15, 2016

Conditions

Psoriasis

Interventions

BIOLOGICAL

Secukinumab

Secukinumab (AIN457) 150 mg, provided in a 1 mL prefilled syringe (one syringe for 150 mg dose, two syringes for the 300 mg dose).

Trial Locations (10)

Novartis Investigative Site, Fukuoka

Novartis Investigative Site, Kitakyushu

Novartis Investigative Site, Asahikawa

Novartis Investigative Site, Sapporo

Novartis Investigative Site, Inashiki-gun

Novartis Investigative Site, Shimotsuke

Novartis Investigative Site, Chiyoda-ku

Novartis Investigative Site, Hachiōji

Novartis Investigative Site, Shinjuku-ku

Novartis Investigative Site, Kofu